跳至主要内容
临床试验/IRCT20191130045556N1
IRCT20191130045556N1招募中3 期

Investigating the Effect of melatonin and magnesium co-supplementation on metabolic, hormonal, inflammatory parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome

Ahvaz University of Medical Sciences0 个研究点目标入组 84 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
84

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 40 years(—)
性别
Female

入选标准

  • Patients with polycystic ovary syndrome based on Rotterdam criteria
  • Age 18-40 years
  • Tendency to participate in the study

排除标准

  • Sleeping disorders
  • The night shift workers
  • ???Any disease that affects metabolic parameters in this trial including Cushing's Syndrome, hypoglycemia, type I or II Diabetes, androgen secreting tumors or congenital adrenal hyperplasia, hyperprolactinemia, hyperparathyroidism, Thyroid disorders, hypertension, Anemia, Allergy, Asthma, Cardiovascular, Kidney, Liver or Pulmonary diseases, Cancer
  • Any drugs that may cause side effects such as menstrual disorders, hirsutism or acne or drugs that affect plasma androgen levels, lipid profile, blood glucose or inflammatory factors during the last 3 months (such as oral contraceptives (OCP), Ovulation induction, anti-androgenic, insulin-sensitizer, blood glucose lowering, anti-obesity, antidepressants, anti-coagulants, Thiazides, Corticosteroids, Metformin, Lipid lowering, NSAIDs, Aspirin)
  • Following the special diet
  • Weight loss of more than 5% body weight in the last 6 months Taking melatonin, magnesium, antioxidant and/or anti-inflammatory supplements within 3 months prior to the enrollment
  • Taking melatonin, magnesium, antioxidant and/or anti-inflammatory supplements within 3 months prior to the enrollment
  • Alcohol consumption
  • Unwillingness to continue cooperation

研究者

相似试验